The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
Any loans to Iran or engagement by the international community is "appeasement," the minister claimed.World Politicsread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
It's that time again! Jim Cramer rang the lightning round bell, which means he gave his take on caller favorite stocks at rapid speed:
Synergy Pharmaceuticals: "I feel like if the data is good you're going to get a takeout bid. If the data is not that good I'm not sure what it's worth. We see with these things like Regulus, if they go right it's just unbelievably good. If they go bad, it's unbelievably bad. And that's why it's been so hard for me to opine on it because it seems very binary to me. And I don't like to comment on the binary. But obviously if the news is good, wow."
Charter Communications Inc: "I like Charter Communications. I happen to like the cable companies very much. This seems to be one of the best domestic businesses. You're in good shape."
Keryx Biopharmaceuticals: "We don't care where a stock has come from, we care where it is going to. This happens to be a stock I have to tell you that I think does have great speculative capabilities. I'm going to say stick with it. I don't want to buy more here because it's had a move, but I do like it because I happen to like the ones that are working on renal that are doing so well in phase three."